May 8, 2020 / 6:45 PM / 18 days ago

NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19

May 8 (Reuters) - The National Institutes of Health said on Friday it has started a clinical study to test a combination of Gilead Sciences Inc’s antiviral drug remdesivir and anti-inflammatory drug baricitinib in COVID-19 patients.

The trial is currently enrolling adults hospitalized with COVID-19 in the United States and is expected to study the treatment combination in more than 1,000 participants. (bit.ly/2YM0tfp)

Baricitinib, which is marketed under brand name Olumiant by Eli Lilly and Co, was being tested as a potential treatment for hospitalized patients diagnosed with COVID-19. (Reporting by Vishwadha Chander in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below